Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-SPACE Hyperthermia with Tislelizumab and Anlotinib in CRPC
NCT06249750Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) (2 arms). Primary endpoint: Biochemical Objective Response Rate at 3 weeks. Started Jan 2024; status: recruiting.
02
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06249750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249750.